Petersen Andreas, Larssen Kjersti W, Gran Frode W, Enger Hege, Hæggman Sara, Mäkitalo Barbro, Haraldsson Gunnsteinn, Lindholm Laura, Vuopio Jaana, Henius Anna Emilie, Nielsen Jens, Larsen Anders R
Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Department of Medical Microbiology, St. Olav Hospital, Trondheim, Norway.
Front Microbiol. 2021 Apr 30;12:668900. doi: 10.3389/fmicb.2021.668900. eCollection 2021.
Methicillin-resistant (MRSA) is notifiable in Denmark, Finland, Iceland, Norway and Sweden. The prevalence of MRSA in this region has been low for many years, but all five countries experience increasing numbers of new cases. The aim of the study was to describe the molecular epidemiology in the Nordic countries 2009-2016. Numbers of new cases of MRSA from 1997 to 2016 were compared, and a database containing information on -type and place of residence or acquisition, for all new MRSA isolates from 2009 to 2016 was established. A website was developed to visualize the geographic distribution of the -types. The incidence of new MRSA cases increased in all Nordic countries with Denmark having 61.8 new cases per 100,000 inhabitants in 2016 as the highest. The number of new cases 2009 to 2016 was 60,984. -typing revealed a high genetic diversity, with a total of 2,344 different -types identified. The majority of these -types (N = 2,017) were found in 1-10 cases. The most common -types t127/CC1, t223/CC22, and t304/CC6:8 increased significantly in all Nordic countries during the study period, except for Iceland, while -type t002/CC5 decreased in the same four countries. The trends of other common -types were different in each of the Nordic countries. The Nordic countries were shown to share similar trends but also to have country-specific characteristics in their MRSA populations. A continued increasing numbers of MRSA will challenge the surveillance economically. A more selected molecular surveillance will probably have to be employed in the future.
耐甲氧西林金黄色葡萄球菌（MRSA）在丹麦、芬兰、冰岛、挪威和瑞典属于应报告疾病。多年来，该地区MRSA的流行率一直较低，但这五个国家的新病例数都在增加。本研究的目的是描述2009年至2016年北欧国家的分子流行病学情况。比较了1997年至2016年MRSA的新病例数，并建立了一个数据库，其中包含2009年至2016年所有新的MRSA分离株的分型及居住或获得地点信息。开发了一个网站来可视化各分型的地理分布。所有北欧国家的MRSA新病例发病率均有所上升，2016年丹麦每10万居民中有61.8例新病例，为最高。2009年至2016年的新病例数为60984例。分型显示出高度的遗传多样性，共鉴定出2344种不同的分型。这些分型中的大多数（N = 2017）在1至10例病例中被发现。在研究期间，除冰岛外，所有北欧国家中最常见的分型t127/CC1、t223/CC22和t304/CC6:8显著增加，而在相同的四个国家中，分型t002/CC5有所下降。其他常见分型在每个北欧国家的趋势各不相同。结果表明，北欧国家在MRSA人群中具有相似的趋势，但也有各自国家的特点。MRSA病例数的持续增加将在经济上对监测工作构成挑战。未来可能不得不采用更有针对性的分子监测方法。
